AUS
NZ
UK
CA
USA
IND
Amcor PLC, the global packaging leader, has submitted its monthly Appendix 4A report revealing a decline of about 3.1 million CHESS Depositary Interests (CDIs) linked to its NYSE-listed ordinary shares during June 2026, ending the month at 140,959,867 CDIs. This reduction corresponds to a net transfer of securities from the ASX-listed CDI structure to ordinary shares held directly on the New York Stock Exchange, which the company described as a routine conversion between the two trading platforms. The report, lodged with the ASX on 3 July 2026, also details movements in Amcor's other securities including options, share rights, and performance rights. For those monitoring Amcor’s dual-listed framework, the monthly CDI fluctuation provides insight into the preferences of institutional and retail investors regarding where they hold their economic interest in the company.<\/p> <\/div>
Key Points<\/h3>
- Company: Amcor PLC (ASX:AMC)<\/li>
- ASX-listed CDIs decreased by 3,101,466 to 140,959,867 as of June 2026, down from 144,061,333 at May 2026 month-end<\/li>
- The CDI decrease matches an equivalent increase of 3,101,466 in NYSE-listed common shares (AMCAQ), which rose to 321,385,823<\/li>
- Options (AMCAK) fell by 165,189 to 8,731,480; share rights (AMCAO) increased by 27,244 to 2,886,422; performance rights (AMCAP) dropped by 67,949 to 3,139,157<\/li>
- Investors should observe if the trend of CDI-to-NYSE share migration continues in future monthly filings<\/li>
<\/ul>
<\/div>
June 2026 CDI Decline Highlights Transfer Activity Between ASX and NYSE Listings<\/h2>
Amcor PLC’s dual-listing structure enables investors to gain economic exposure either through ASX-quoted CDIs or directly via NYSE-listed common shares. The June 2026 Appendix 4A confirms a net reduction of 3,101,466 CDIs during the month, lowering the CDI total from 144,061,333 at May’s end to 140,959,867 at June’s close. The company explained this change as resulting from net transfers of securities between the ASX CDI structure and NYSE ordinary shares, a standard process within such dual-listed arrangements.<\/p>
The CDI mechanism permits Australian investors to trade Amcor shares on the ASX in Australian dollars, with each CDI representing a one-for-one economic interest in an underlying NYSE-listed ordinary share. When investors convert CDIs into NYSE shares, the ASX CDI count decreases while the NYSE share count rises equivalently. This is exactly reflected in the June 2026 figures, with the company confirming the movements as routine transmutations between the two markets.<\/p>
NYSE Common Shares Increase Confirms One-to-One Conversion Process<\/h2>
The corresponding rise in Amcor’s NYSE-listed common shares (ASX code: AMCAQ) highlights the mechanical nature of these changes. The total common shares on issue at June 30, 2026, stood at 321,385,823, up from 318,284,357 at May 31, 2026 — a net increase of exactly 3,101,466, matching the CDI decrease. The company attributed this to conversions between ASX CDIs and NYSE shares.<\/p>
This symmetrical movement aligns with Amcor’s 1:1 CDI-to-share ratio, providing transparency for investors tracking total share counts. The combined total of CDIs and NYSE shares represents the same pool of underlying shares, differing only by the venue chosen by holders. No new shares were issued or cancelled during these transfers, leaving the overall economic interest unchanged.<\/p>
Options Pool Contracts by 165,189 in June Due to Grants, Distributions, and Expiries<\/h2>
In addition to CDI and common share changes, Amcor’s monthly report details movements in employee and executive incentive securities. The options (ASX code: AMCAK) decreased by 165,189 during June 2026, from 8,896,669 at May’s end to 8,731,480 at month-end. The company cited the net effect of grants, distributions, and expiries as the cause.<\/p>
At large multinational companies like Amcor, option pools fluctuate monthly as older tranches expire, new grants are issued, or options are exercised and converted into shares. The June net reduction suggests expiries and distributions exceeded new grants, although the company did not disclose a detailed breakdown of these movements. Investors monitoring dilution risk or executive compensation should watch the option pool trends in upcoming filings.<\/p>
Share Rights Increase Slightly as Grants Outpace Distributions and Expiries<\/h2>
Amcor’s share rights (ASX code: AMCAO) rose modestly by 27,244 in June 2026, reaching 2,886,422 at month-end, compared to 2,859,178 at May’s close. The company attributed the change to the net balance of grants, distributions, and expiries, consistent with other incentive securities.<\/p>
Unlike options, share rights typically vest and convert into ordinary shares upon meeting certain conditions such as service or performance milestones. The slight increase indicates new grants exceeded conversions and lapses during June. As with options, no detailed breakdown was provided in this filing.<\/p>
Performance Rights Decrease by 67,949 Amid Net Settlement Activity in June 2026<\/h2>
Performance rights (ASX code: AMCAP), described as "Performance Rights Shares," declined by 67,949 during June 2026, falling from 3,207,106 at May’s end to 3,139,157 at June’s close. The company noted this reflects the net difference between grants, distributions, and expiries.<\/p>
Performance rights are generally awarded to senior executives under long-term incentive plans, with vesting contingent on achieving specified financial or strategic targets over multiple years. The net decline suggests more rights were settled or lapsed than granted in June. Investors focused on executive incentives and dilution should consider this trend alongside Amcor’s broader remuneration disclosures.<\/p>
Implications of June 2026 CDI Migration for Amcor’s Investor Composition<\/h2>
The transfer of over three million securities from ASX CDIs to NYSE shares in one month is significant for a company of Amcor’s size. Incorporated in the UK and reporting primarily in US dollars, Amcor’s NYSE listing reflects its substantial North American operations. The ongoing shift from ASX CDIs to NYSE shares may indicate institutional investors consolidating holdings in New York, although the company did not comment on the drivers behind this activity.<\/p>
Alternatively, the transfers could be driven by custodial, settlement, or portfolio rebalancing needs rather than valuation differences between markets. Such transmutations are common in dual-listed companies and do not inherently signal buying or selling pressure. Nonetheless, investors and analysts tracking Amcor’s ASX liquidity may find it valuable to monitor this trend in future Appendix 4A filings to see if the CDI count continues to decline.<\/p>
Understanding Amcor’s Dual Listing and the Importance of Monthly CDI Reports for ASX Investors<\/h2>
Amcor holds a foreign exempt listing on the ASX, primarily regulated by its home exchange but required to provide periodic disclosures to Australian investors, including monthly Appendix 4A CDI reports. These filings give ASX-listed investors visibility of the total CDIs on issue monthly and allow tracking of changes over time. The 1:1 CDI-to-share ratio ensures CDI holders have the same economic rights as direct NYSE shareholders, including dividends and distributions.<\/p>
For Australian retail and institutional investors preferring to trade in Australian dollars on the ASX, CDIs offer an important access point to Amcor’s equity. With approximately 141 million CDIs and about 321 million NYSE common shares outstanding, the majority of Amcor’s issued capital is held through the US market, reflecting its global investor base and operational focus in North America.<\/p>
No Financial or Operational Updates Included in June 2026 Filing<\/h2>
Investors should note that the Appendix 4A filing is an administrative securities register update and does not include financial results, earnings guidance, operational data, or strategic commentary. Amcor did not disclose revenue, profit forecasts, production figures, or other forward-looking financial metrics in this update. Assessments of Amcor’s financial performance should rely on separate earnings releases, investor presentations, and regulatory filings on both the ASX and US Securities and Exchange Commission.<\/p>
The filing’s immediate impact on share price was unclear, as such submissions are typically routine and not market-moving. Investors interested in Amcor’s near-term outlook should focus on upcoming quarterly or half-year financial reports, changes in earnings guidance, and broader industry and macroeconomic factors. The next major event to watch is Amcor’s forthcoming substantive financial or operational disclosure.<\/p>
Summary of Amcor’s Security Counts Entering Second Half of 2026<\/h2>
The June 2026 Appendix 4A provides a consolidated view of Amcor’s outstanding securities at mid-year. As of June 30, 2026, Amcor had 140,959,867 CDIs on the ASX, 321,385,823 NYSE common shares, 8,731,480 options, 2,886,422 share rights, and 3,139,157 performance rights. These figures form the basis for calculating fully diluted share counts and assessing potential dilution from incentive securities.<\/p>
The combined total of approximately 462.3 million CDIs and common shares outlines Amcor’s equity base heading into the second half of the fiscal year. Future movements in options, share rights, and performance rights pools should be monitored for any significant changes that might affect executive remuneration or the incentive framework. Investors are advised to consider this filing alongside Amcor’s other public disclosures to gain a comprehensive understanding of the company’s capital structure and strategic direction.<\/p>
June 2026 CDI Decline Highlights Transfer Activity Between ASX and NYSE Listings<\/h2>
Amcor PLC’s dual-listing structure enables investors to gain economic exposure either through ASX-quoted CDIs or directly via NYSE-listed common shares. The June 2026 Appendix 4A confirms a net reduction of 3,101,466 CDIs during the month, lowering the CDI total from 144,061,333 at May’s end to 140,959,867 at June’s close. The company explained this change as resulting from net transfers of securities between the ASX CDI structure and NYSE ordinary shares, a standard process within such dual-listed arrangements.<\/p>
The CDI mechanism permits Australian investors to trade Amcor shares on the ASX in Australian dollars, with each CDI representing a one-for-one economic interest in an underlying NYSE-listed ordinary share. When investors convert CDIs into NYSE shares, the ASX CDI count decreases while the NYSE share count rises equivalently. This is exactly reflected in the June 2026 figures, with the company confirming the movements as routine transmutations between the two markets.<\/p>
NYSE Common Shares Increase Confirms One-to-One Conversion Process<\/h2>
The corresponding rise in Amcor’s NYSE-listed common shares (ASX code: AMCAQ) highlights the mechanical nature of these changes. The total common shares on issue at June 30, 2026, stood at 321,385,823, up from 318,284,357 at May 31, 2026 — a net increase of exactly 3,101,466, matching the CDI decrease. The company attributed this to conversions between ASX CDIs and NYSE shares.<\/p>
This symmetrical movement aligns with Amcor’s 1:1 CDI-to-share ratio, providing transparency for investors tracking total share counts. The combined total of CDIs and NYSE shares represents the same pool of underlying shares, differing only by the venue chosen by holders. No new shares were issued or cancelled during these transfers, leaving the overall economic interest unchanged.<\/p>
Options Pool Contracts by 165,189 in June Due to Grants, Distributions, and Expiries<\/h2>
In addition to CDI and common share changes, Amcor’s monthly report details movements in employee and executive incentive securities. The options (ASX code: AMCAK) decreased by 165,189 during June 2026, from 8,896,669 at May’s end to 8,731,480 at month-end. The company cited the net effect of grants, distributions, and expiries as the cause.<\/p>
At large multinational companies like Amcor, option pools fluctuate monthly as older tranches expire, new grants are issued, or options are exercised and converted into shares. The June net reduction suggests expiries and distributions exceeded new grants, although the company did not disclose a detailed breakdown of these movements. Investors monitoring dilution risk or executive compensation should watch the option pool trends in upcoming filings.<\/p>
Share Rights Increase Slightly as Grants Outpace Distributions and Expiries<\/h2>
Amcor’s share rights (ASX code: AMCAO) rose modestly by 27,244 in June 2026, reaching 2,886,422 at month-end, compared to 2,859,178 at May’s close. The company attributed the change to the net balance of grants, distributions, and expiries, consistent with other incentive securities.<\/p>
Unlike options, share rights typically vest and convert into ordinary shares upon meeting certain conditions such as service or performance milestones. The slight increase indicates new grants exceeded conversions and lapses during June. As with options, no detailed breakdown was provided in this filing.<\/p>
Performance Rights Decrease by 67,949 Amid Net Settlement Activity in June 2026<\/h2>
Performance rights (ASX code: AMCAP), described as "Performance Rights Shares," declined by 67,949 during June 2026, falling from 3,207,106 at May’s end to 3,139,157 at June’s close. The company noted this reflects the net difference between grants, distributions, and expiries.<\/p>
Performance rights are generally awarded to senior executives under long-term incentive plans, with vesting contingent on achieving specified financial or strategic targets over multiple years. The net decline suggests more rights were settled or lapsed than granted in June. Investors focused on executive incentives and dilution should consider this trend alongside Amcor’s broader remuneration disclosures.<\/p>
Implications of June 2026 CDI Migration for Amcor’s Investor Composition<\/h2>
The transfer of over three million securities from ASX CDIs to NYSE shares in one month is significant for a company of Amcor’s size. Incorporated in the UK and reporting primarily in US dollars, Amcor’s NYSE listing reflects its substantial North American operations. The ongoing shift from ASX CDIs to NYSE shares may indicate institutional investors consolidating holdings in New York, although the company did not comment on the drivers behind this activity.<\/p>
Alternatively, the transfers could be driven by custodial, settlement, or portfolio rebalancing needs rather than valuation differences between markets. Such transmutations are common in dual-listed companies and do not inherently signal buying or selling pressure. Nonetheless, investors and analysts tracking Amcor’s ASX liquidity may find it valuable to monitor this trend in future Appendix 4A filings to see if the CDI count continues to decline.<\/p>
Understanding Amcor’s Dual Listing and the Importance of Monthly CDI Reports for ASX Investors<\/h2>
Amcor holds a foreign exempt listing on the ASX, primarily regulated by its home exchange but required to provide periodic disclosures to Australian investors, including monthly Appendix 4A CDI reports. These filings give ASX-listed investors visibility of the total CDIs on issue monthly and allow tracking of changes over time. The 1:1 CDI-to-share ratio ensures CDI holders have the same economic rights as direct NYSE shareholders, including dividends and distributions.<\/p>
For Australian retail and institutional investors preferring to trade in Australian dollars on the ASX, CDIs offer an important access point to Amcor’s equity. With approximately 141 million CDIs and about 321 million NYSE common shares outstanding, the majority of Amcor’s issued capital is held through the US market, reflecting its global investor base and operational focus in North America.<\/p>
No Financial or Operational Updates Included in June 2026 Filing<\/h2>
Investors should note that the Appendix 4A filing is an administrative securities register update and does not include financial results, earnings guidance, operational data, or strategic commentary. Amcor did not disclose revenue, profit forecasts, production figures, or other forward-looking financial metrics in this update. Assessments of Amcor’s financial performance should rely on separate earnings releases, investor presentations, and regulatory filings on both the ASX and US Securities and Exchange Commission.<\/p>
The filing’s immediate impact on share price was unclear, as such submissions are typically routine and not market-moving. Investors interested in Amcor’s near-term outlook should focus on upcoming quarterly or half-year financial reports, changes in earnings guidance, and broader industry and macroeconomic factors. The next major event to watch is Amcor’s forthcoming substantive financial or operational disclosure.<\/p>
Summary of Amcor’s Security Counts Entering Second Half of 2026<\/h2>
The June 2026 Appendix 4A provides a consolidated view of Amcor’s outstanding securities at mid-year. As of June 30, 2026, Amcor had 140,959,867 CDIs on the ASX, 321,385,823 NYSE common shares, 8,731,480 options, 2,886,422 share rights, and 3,139,157 performance rights. These figures form the basis for calculating fully diluted share counts and assessing potential dilution from incentive securities.<\/p>
The combined total of approximately 462.3 million CDIs and common shares outlines Amcor’s equity base heading into the second half of the fiscal year. Future movements in options, share rights, and performance rights pools should be monitored for any significant changes that might affect executive remuneration or the incentive framework. Investors are advised to consider this filing alongside Amcor’s other public disclosures to gain a comprehensive understanding of the company’s capital structure and strategic direction.<\/p>
